|Place of Origin:||China|
|Model Number:||Tizanidine hydrochloride|
|Minimum Order Quantity:||1KG|
|Packaging Details:||Aluminum foil bag|
|Payment Terms:||L/C, D/A, D/P, T/T, Western Union, MoneyGram，Alibaba Assurance Order|
|Other Name:||TIZANIDINE HCL||Appearance:||White Crystalline Powder|
Pharmaceutical Tizanidine Hydrochloride Powder,
99% Tizanidine Hydrochloride,
64461-82-1 API Pharmaceutical
64461-82-1 API Pharmaceutical Grade 99% Tizanidine hydrochloride Powder
The Introductction of Tizanidine hydrochloride
Tizanidine hydrochloride, an imidazoline m-diazepentene derivative with a molecular weight of 290.17, has a structure similar to that of colistin and a melting point of 280°C. The chemical name is 5-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-2,1,3-benzothiadiazol-4-amine hydrochloride, which was developed by Novartis, Switzerland. It is a central skeletal muscle relaxant with an imidazoline structure developed by Novartis, Switzerland.
Tizanidine hydrochloride is used clinically for the treatment of skeletal muscle hypertonia, myospasm and myotonia due to central injury. It is effective in tension headache, trigeminal neuralgia and myofascial pain syndrome. It can also be used as an adjunct to general or regional anesthesia, preoperative and postoperative sedative, and postoperative analgesic.
Tizanidine hydrochloride relieves spasticity without causing muscle weakness, does not produce psychological dependence at therapeutic doses, and is a well-tolerated and efficacious central muscle relaxant.
Tizanidine hydrochloride is used for the treatment of skeletal muscle hypertonia, myospasm and myotonia due to traumatic brain and spinal cord injury, cerebral hemorrhage, encephalitis, and multiple sclerosis.
Toxic side effects
When tizanidine hydrochloride tablets are applied at the recommended low dose to relieve painful myospasm, adverse effects are rare and include drowsiness, fatigue, dizziness, dry mouth, nausea, gastrointestinal disturbances, and a mild decrease in blood pressure, usually mild and transient. These adverse reactions, mainly drowsiness, dry mouth, and dizziness, are more common and pronounced when applying the recommended high dose of tizanidine hydrochloride tablets for the treatment of central myasthenia gravis, although they are rarely severe enough to warrant discontinuation of therapy.
|Product Name||Tizanidine hydrochloride||Batch No.||HNB-220302|
|Issuing Date||2022.03.02||Expiry Date||2024.03.02|
|Test parameter||Test Iimit||Results|
|Appearance||White or slightly yellowish crystalline powder||White crystalline Powder|
|C: Test of sodium salt||Conforms|
|Appearance of Solution||5% of methanol solution 440nm, ≤0.05%||0.011|
|Clarity of solution||Equal to methanol||Pass|
|Related Substances||Any specified impurity: ≤0.2%||Not detected|
|Any unspecified impurity: ≤0.1%||Not detected|
|Total impurty:≤0.5%||Not detected|
|Loss on drying||≤0.5%(1g, 100~105℃,3hrs)||0.2%|
|Conclusion||The above material complies with USP 34 standard|